Andreas Eckert
Clinical Researcher
Data updated
Papers
Trials
Research Footprint
Andreas Eckert appears in 18 tracked papers (2019–2026), most studied alongside MDMA, LSD and Psilocybin, across Healthy Volunteers, Medicinal Chemistry & Drug Development and Anxiety Disorders.
Most-cited paper: Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. (248 citations).
Frequent co-authors: Matthias Liechti, Nikhil Varghese and Friederike Holze.
Publication Landscape
How the 18 papers Blossom tracks for Andreas Eckert line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of August 2026, not a complete bibliography.
How has Andreas Eckert's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 18 of 18 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Andreas Eckert publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Andreas Eckert publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Andreas Eckert is a clinical researcher active in experimental human psychopharmacology with a focus on acute-phase studies of classical psychedelics and entactogens. He has co‑authored multiple randomised, double‑blind, placebo‑controlled and crossover trials in healthy volunteers examining the acute subjective, physiological and receptor‑mediated effects of compounds including LSD, psilocybin, DMT and several MDMA variants. His work frequently appears in collaborations that probe dose‑responses, stereoisomer differences, drug–drug interactions (for example SSRI pretreatment) and the role of the 5‑HT2A receptor in mediating acute psychedelic effects.
Key Impact
Notable for contributions to controlled human experimental studies characterising acute effects, pharmacology and receptor mechanisms of serotonergic and entactogenic compounds.
Collaboration Network
26 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Andreas Eckert's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Andreas Eckert is associated with.
University of Basel
academicThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →